GAMMA Investing’s Damora Therapeutics DMRA Stock Holding History

GAMMA Investing’s Portfolio DMRA Stock Details DMRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.94K	Buy	+91	New	+$2.57K	﹤0.01%	3961

Other funds holding DMRA

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Parkside Financial Bank & Trust Saint Louis, Missouri $1.51B AUM 17.86% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $993M AUM 16.29% 1-Year Est. Return

GAMMA Investing's DMRA Position: Q3 2026 in Review

GAMMA Investing opened a new position in Damora Therapeutics (DMRA) in Q3 2026: 91 shares worth $1.94K. The stake represents ﹤0.01% of the portfolio and ranks #3961 among its holdings.

10 funds tracked by Wall St. Rank hold DMRA as of Q3 2026.

GAMMA Investing held 91 shares of Damora Therapeutics worth $1.94K as of Q3 2026.
Damora Therapeutics was a new GAMMA Investing position in Q3 2026.
Damora Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3961 holding.
10 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.